Osteobios

Calcitonin Human - Calcium Carbonate - Calcium Fluoride - Calcium Phosphate - Isoleucine - Leucine - Lysine - Methionine - Phenylalanine - Sus Scrofa Bone - Sus Scrofa Parathyroid Gland - Threonine - Tryptophan - Valine -


Guna Spa
Human Otc Drug
NDC 17089-259
Osteobios also known as Calcitonin Human - Calcium Carbonate - Calcium Fluoride - Calcium Phosphate - Isoleucine - Leucine - Lysine - Methionine - Phenylalanine - Sus Scrofa Bone - Sus Scrofa Parathyroid Gland - Threonine - Tryptophan - Valine - is a human otc drug labeled by 'Guna Spa'. National Drug Code (NDC) number for Osteobios is 17089-259. This drug is available in dosage form of Solution/ Drops. The names of the active, medicinal ingredients in Osteobios drug includes Calcitonin Human - 6 [hp_X]/30mL Calcium Carbonate - 30 [hp_X]/30mL Calcium Fluoride - 30 [hp_X]/30mL Calcium Phosphate - 30 [hp_X]/30mL Isoleucine - 3 [hp_X]/30mL Leucine - 3 [hp_X]/30mL Lysine - 3 [hp_X]/30mL Methionine - 3 [hp_X]/30mL Phenylalanine - 3 [hp_X]/30mL Sus Scrofa Bone - 30 [hp_X]/30mL and more. The currest status of Osteobios drug is Active.

Drug Information:

Drug NDC: 17089-259
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Osteobios
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Calcitonin Human - Calcium Carbonate - Calcium Fluoride - Calcium Phosphate - Isoleucine - Leucine - Lysine - Methionine - Phenylalanine - Sus Scrofa Bone - Sus Scrofa Parathyroid Gland - Threonine - Tryptophan - Valine -
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Guna Spa
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Solution/ Drops
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CALCITONIN HUMAN - 6 [hp_X]/30mL
CALCIUM CARBONATE - 30 [hp_X]/30mL
CALCIUM FLUORIDE - 30 [hp_X]/30mL
CALCIUM PHOSPHATE - 30 [hp_X]/30mL
ISOLEUCINE - 3 [hp_X]/30mL
LEUCINE - 3 [hp_X]/30mL
LYSINE - 3 [hp_X]/30mL
METHIONINE - 3 [hp_X]/30mL
PHENYLALANINE - 3 [hp_X]/30mL
SUS SCROFA BONE - 30 [hp_X]/30mL
SUS SCROFA PARATHYROID GLAND - 30 [hp_X]/30mL
THREONINE - 3 [hp_X]/30mL
TRYPTOPHAN - 3 [hp_X]/30mL
VALINE - 3 [hp_X]/30mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 23 May, 2006
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 07 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Guna spa
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0317089259183
UPC stands for Universal Product Code.
UNII:I0IO929019
H0G9379FGK
O3B55K4YKI
97Z1WI3NDX
04Y7590D77
GMW67QNF9C
K3Z4F929H6
AE28F7PNPL
47E5O17Y3R
597RLJ09RG
2KBE35NE8S
2ZD004190S
8DUH1N11BX
HG18B9YRS7
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Blood Coagulation Factor [EPC]
Calcium [CS]
Cations
Divalent [CS]
Increased Coagulation Factor Activity [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
17089-259-181 BOTTLE, DROPPER in 1 BOX (17089-259-18) / 30 mL in 1 BOTTLE, DROPPER01 May, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses temporary relief of symptoms related weak bones such as: frequent and slow-healing fractures sharp and dull bone pain

Product Elements:

Osteobios calcitonin human - calcium carbonate - calcium fluoride - calcium phosphate - isoleucine - leucine - lysine - methionine - phenylalanine - sus scrofa bone - sus scrofa parathyroid gland - threonine - tryptophan - valine - alcohol calcitonin human calcitonin human isoleucine isoleucine leucine leucine lysine lysine methionine methionine phenylalanine phenylalanine threonine threonine tryptophan tryptophan valine valine calcium carbonate calcium cation carbonate ion calcium fluoride fluoride ion calcium phosphate calcium cation sus scrofa bone sus scrofa bone sus scrofa parathyroid gland sus scrofa parathyroid gland

Indications and Usage:

Take 15 minutes before meals

Warnings:

Warnings stop use and ask doctor if symptoms persist more than 5 days. if pregnant or breast-feeding ask a health professional before use. keep out of reach of children . in case of overdose, get medical help or contact a poison control center right away. contains ethyl alcohol 30%

Dosage and Administration:

Directions adults and children 12 years and older 20 drops in a little water, 2 times per day children between 12 years and 6 years of age 10 drops in a little water, 2 times per day children under 6 years 5 drops in a glass of water, 2 times per day

Package Label Principal Display Panel:

Principal display panel 5usost-rev05-03-04-18

Further Questions:

Questions questions?: info@gunainc.com, tel. (484) 223-3500


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.